Not Signed In -
Warts, Genital |
Anal Warts |
Clinical Trial: Study with a Topical Gel to Treat Common Warts in Adults
This study is no longer recruiting patients.
|
Purpose
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.
A second purpose is to evaluate the safety of the drug.
| Condition | Intervention | Phase |
|---|---|---|
| Warts | Drug: Resiquimod | Phase II |
MedlinePlus related topics: Warts
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Single Blind, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Official Title: A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for Up to 12 Weeks for the Treatment of Common Warts in Adults
Secondary Outcomes: Partial clearance of treated wart(s)
Expected Total Enrollment: 48
Study start: October 2004; Study completion: May 2006
Last follow-up: November 2005; Data entry closure: December 2005
Eligibility
Inclusion Criteria:
- Diagnosis of common warts
- Two forms of birth control
Exclusion Criteria:
Location Information
More Information
Last Updated: July 25, 2005
Record first received: July 8, 2005
ClinicalTrials.gov Identifier: NCT00117871
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-02
email this page
print this page
bookmark this page
feedback on this page
